Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, has announced the approval of equity inducement grants for seven new non-officer employees. The grants, approved by the company's Compensation Committee, consist of 53,550 share options with an exercise price of $29.04 per common share, reflecting the closing price on May 29, 2025. These options are part of the company's 2025 Inducement Equity Incentive Plan and will vest over four years: 25% on the first anniversary of the employee's start date, with the remainder vesting monthly over the subsequent three years. The options have a 10-year term.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。